The use of biomarkers in surveillance, medical screening, and intervention

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 592, Issue 1-2, 2005, Pages 155-163

  Schulte, Paul A ^a  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Biomarkers; Intervention; Risk assessment; Screening; Surveillance

Indexed keywords

BIOLOGICAL MARKER; GLUTATHIONE TRANSFERASE;

BIOLOGICAL MONITORING; CONFERENCE PAPER; DISEASE PREDISPOSITION; ENVIRONMENTAL MONITORING; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HAZARD ASSESSMENT; HIGH RISK POPULATION; HUMAN; LIFESTYLE; MEDICAL DECISION MAKING; MEDICAL RECORD; OCCUPATIONAL HAZARD; PRIORITY JOURNAL; PUBLIC HEALTH; RISK ASSESSMENT; SAMPLE SIZE; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; DIAGNOSIS; DISEASE SUSCEPTIBILITY; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGY, MOLECULAR; HUMANS; MASS SCREENING; PROGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 28244440908     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2005.06.019     Document Type: Conference Paper

References (47)

1. R.J. Albertini Mechanistic insights from biomarker studies: somatic mutations and rodent/human comparisons following exposure to a potential carcinogen IARC Sci. Publ. 157 2004 153 177
2. P.A. Schulte F.P. Perera Molecular Epidemiology: Principles and Practice 1993 Academic Press, Inc. San Diego, CA
3. W. Burke, D. Atkins, M. Gwinn, A. Guttmacher, J. Haddow, J. Lau, G. Palomaki, N. Press, C.S. Richards, L. Wideroff, and G.L. Wiesner Genetic test evaluation: information needs of clinicians, policy makers, and the public Am. J. Epidemiol. 156 2002 311 318
4. P.A. Schulte Some implications of genetic biomarkers in occupational epidemiology and practice Scand. J. Work Environ. Health 30 2004 71 79
5. B.A. Conley, and S.E. Taube Prognostic and predictive markers for cancer Dis. Markers 20 2004 35 43
6. K. VanDamme, L. Casteleyn, E. Heseltine, A. Huici, M. Sorsa, N. van Larebeke, and P. Vineis Individual susceptibility and prevention of occupational diseases: scientific and ethical issues J. Occup. Environ. Med. 37 1 1995 91 99
7. M.A. Rothstein Genetic Secrets: Protecting Privacy and Confidentiality in the Genetic Era 1997 Yale University Press New Haven, CT
8. P.A. Schulte, G.P. Lomax, E.M. Ward, and M.J. Colligan Ethical issues in the use of genetic markers in occupational epidemiologic research J. Occup. Environ. Med. 41 8 1999 639 646
9. N.A. Ashford, C.J. Spadafor, D.B. Hattis, and C.C. Caldart Monitoring the Worker for Exposure and Disease: Scientific, Legal and Ethical Considerations in the Use of Biomarkers 1990 The Johns Hopkins University Press Baltimore, MD
10. P. Vineis, P. Schulte, and A.J. McMichael Misconceptions about the use of genetic tests in populations Lancet 357 2001 709 712
11. W.W. Grody Ethical issues raised by genetic testing with oligonucleotide microarrays Mol. Biotechnol. 23 2003 127 138
12. A. Schatzkin, L.S. Freedman, M.H. Schiffman, and S.M. Dawsey Validation of intermediate end points in cancer research J. Natl. Cancer Inst. 82 1990 1746 1752
13. R.J. Albertini Validated biomarker responses influence medical surveillance of individuals exposed to genotoxic agents Radiat. Prot. Dosimetry 97 2001 47 54
14. R. Ottoman Gene-environment interaction: definitions and study designs Prev. Med. 25 1996 764 770
15. J.R. Paul Clinical Epidemiology 1958 University of Chicago Press Chicago, IL
16. J.A. Knottnerus, and J.W. Muris Assessment of the accuracy of diagnostic tests: the cross-sectional study J. Clin. Epidemiol. 56 2003 1118 1128
17. D.F. Ransohoff Challenges and opportunities in evaluating diagnostic tests J. Clin. Epidemiol. 55 2002 1178 1182
18. M. Ogata, T. Numano, M. Hosokawa, and H. Michitsuji Large-scale biological monitoring in Japan Sci. Total Environ. 199 1997 197 204
19. M.S. Morgan The biological exposure indices: a key component in protecting workers from toxic chemicals Environ. Health Perspect. 105 1997 105 115
20. M.S. Morgan, and K.H. Schaller An analysis of criteria for biological limit values developed in Germany and in the United States Int. Arch. Occup. Environ. Health 72 1999 195 204
21. A.S. Yassin, J.F. Martonik, and J.L. Davidson Blood lead levels in U.S. workers, 1988-1994 J. Occup. Environ. Med. 46 2004 720 728
22. S. Lormphongs, K. Miyashita, I. Morioka, C. Chaikittiporn, N. Miyai, and H. Yamamoto Lead exposure and blood lead level of workers in a battery manufacturing plant in Thailand Ind. Health 41 2003 348 353
23. P.A. Schulte Interpretation of genetic data for medical and public health uses G. Arnason S. Nordal V. Arnason Blood and Data: Ethical, Legal, and Social Aspects of Human Genetic Databases 2004 University of Iceland Press, and Centre for Ethics Reykjavik, Iceland 277 282
24. G. Arnason S. Nordal V. Arnason Blood and Data: Ethical, Legal and Social Aspects of Human Genetic Databases 2004 University of Iceland Press and Centre for Ethics Reykjavik, Iceland
25. G.P. Hemstreet, and W. Wang Genotypic and phenotypic biomarker profiles for individual risk assessment and cancer detection (lessons from bladder cancer risk assessment in symptomatic patients and workers exposed to benzidine) Front Biosci. 9 2004 2671 2679
26. T.C. Kennedy, and F.R. Hirsch Using molecular markers in sputum for the early detection of lung cancer: a review Lung Cancer 45 Suppl. 2 2004 S21 S27
27. R.A. Smith, V. Cokkinides, A.C. von Eschenbach, B. Levin, C. Cohen, C.D. Runowicz, S. Sener, D. Saslow, and H.J. Eyre American Cancer Society guidelines for the early detection of cancer CA Cancer J. Clin. 52 2002 8 22
28. E.L. Baker, and T.P. Matte Surveillance of occupational illness and injury W. Halperin E.L. Baker Jr. R.R. Monson Public Health Surveillance 1992 1992 Van Nostrand Reinhold New York, NY 178 194
29. W. Burke, L.E. Pinsky, and N.A. Press Categorizing genetic tests to identify their ethical, legal, and social implications Am. J. Med. Genet. 106 2001 233 240
30. S.T. Bogardus Jr., J. Concato, and A.R. Feinstein Clinical epidemiological quality in molecular genetic research: the need for methodological standards JAMA 281 1999 1919 1926
31. P.W. Brandt-Rauf, and S.I. Brandt-Rauf Genetic testing in the workplace: ethical, legal, and social implications Annu. Rev. Public Health 25 2004 139 153
32. R.J. McCunney Genetic testing: ethical implications in the workplace Occup. Med. State Art Rev. 17 2002 665 672
33. N.A. Holtzman Ethical aspects of genetic testing in the workplace Community Genet. 6 2003 136 138
34. A. Schatzkin, L.S. Freedman, J. Dorgan, L.M. McShane, M.H. Schiffman, and S.M. Dawsey Surrogate end points in cancer research: a critique Cancer Epidemiol. Biomarkers Prev. 5 1996 947 953
35. D.C. Christiani Utilization of biomarker data for clinical and environmental intervention Environ. Health Perspect. 104 1996 921 925
36. F.Y. Bois, G. Krowech, and L. Zeise Modeling human interindividual variability in metabolism and risk: the example of 4-aminobiphenyl Risk Anal. 15 1995 205 213
37. H.A. El-Masri, D.A. Bell, and C.J. Portier Effects of glutathione transferase theta polymorphism on the risk estimates of dichloromethane to humans Toxicol. Appl. Pharmacol. 158 1999 221 230
38. H. Toyoshiba, T. Yamanaka, H. Sone, F.M. Parham, N.J. Walker, J. Martinez, and C. Portier Gene interaction network suggests dioxin induces a significant linkage between aryl hydrocarbon receptor and retinoic acid receptor beta Environ. Health Perspect. 112 2004 1217 1224
39. M.D. Waters, K. Olden, and R.W. Tennant Toxicogenomic approach for assessing toxicant-related disease Mutat. Res./Rev. Mutat. Res. 544 2003 415 424
40. K. Freeman Toxicogenomics data: the road to acceptance Environ. Health Perspect. 112 2004 A678 A685
41. E. McCanlies, D.P. Landsittel, B. Yucesoy, V. Vallyathan, M.L. Luster, and D.S. Sharp Significance of genetic information in risk assessment and individual classification using silicosis as a case model Ann. Occup. Hyg. 46 2002 375 381
42. A.S. Glas, J.G. Lijmer, M.H. Prins, G.J. Bonsel, and P.M. Bossuyt The diagnostic odds ratio: a single indicator of test performance J. Clin. Epidemiol. 56 2003 1129 1135
43. R.J. Cook, and D.L. Sackett The number needed to treat: a clinically useful measure of treatment effect BMJ 310 1995 452 454
44. H.T. Davies Interpreting measures of treatment effect Hosp. Med. 59 1998 499 501
45. C.M. Rembold Number needed to screen: development of a statistic for disease screening BMJ 317 1998 307 312
46. S.A. Musich, W.N. Burton, and D.W. Edington Cost and benefits of prevention and disease management Dis. Manage. Health Outcomes 5 1999 153 166
47. V. Goel for Crossroads 99 Group Appraising organised screening programmes for testing for genetic susceptibility to cancer BMJ 322 2001 1174 1178